Commonly Reported Side Effects Injection site irritation : Redness, swelling, or slight bruising at subcutaneous sites Mild fatigue or lethargy : Especially when first adjusting to mitochondrial AMPK activation Hunger changes : Some users report appetite suppression, while others feel more hungry due to enhanced fat mobilization Muscle cramping : Rare, possibly due to increased fatty acid metabolism and electrolyte shifts Rare or Theoretical Risks Hypoglycemia : Very rare, but theoretically possible when combined with fasting, Clean Carbs, or insulin-sensitizing stacks Disrupted thyroid or cortisol rhythms : Only in extremely high or prolonged usage Hormonal suppression : MOTSc does not suppress testosterone or endogenous growth hormone like anabolic steroids might No significant adverse effects were observed following repeated MOTSc administration in animal models or early-phase human data. Kim et al., Cell Metabolism Safety Summary Short-term use appears safe in healthy individuals Long-term safety in humans remains under investigation Not recommended during pregnancy, adolescence, or for those with active cancers Always consult a licensed medical provider before use Legal Status and WADA Compliance of MOTSc While MOTSc is naturally produced in the body, exogenous use (via injection) places it in a restricted category for athletes and may fall into legal gray zones depending on country and purpose
But the glucagon receptor component is what truly separates retatrutide from everything else on the market
For a Canadian buyer, the practical appeal is straightforward
Research suggests that the peptide may help improve the function of joints, particularly in cases where cartilage damage has occurred
These users report appreciating treatment benefits while active but watching improvements gradually fade over months post-discontinuation, with timeline showing first 2 months maintaining most benefits creating initial optimism, months 2-4 showing noticeable decline returning toward baseline, months 4-8 continuing regression approaching pre-treatment status, and stabilization occurring 60-80% back toward original baseline with only modest long-term improvement retention
